From the Division of Otolaryngology Head and Neck Surgery, Montreal University Hospital Center (CHUM), Montreal, Quebec, Canada.
Otol Neurotol. 2014 Jun;35(5):889-94. doi: 10.1097/MAO.0000000000000272.
Review the useful hearing preservation and tumor control outcomes of microsurgery (MS), stereotactic radiation (SR), conservative management (CM), and chemotherapy (ChT) for Neurofibromatosis type 2 vestibular schwannomas.
Ovid MEDLINE was used to conduct a thorough search of English-language publications dating from 1948 to February 2013.
Patients must have had useful hearing at diagnosis and treated with one of the 4 treatments as their primary therapy. All sporadic vestibular schwannoma cases were excluded.
A total of 19 articles were reviewed. Hearing preservation was defined as unchanged or improved useful hearing. Tumor control was defined as no change in size or tumor regression for SR, CM, and ChT-treated cases, and as no recurrence for MS treated cases.
Microsurgery seems to have the worse overall results, while SR has very good tumor control with poor useful hearing preservation. If a patient qualifies for CM, he is likely to show the most satisfactory results with the least treatment available. A close follow-up on ChT clinical trials and possible side-effects is warranted as preliminary short-term results are quite favorable. Additional long-term studies are required for a better understanding of this disease.
回顾神经纤维瘤病 2 型前庭神经鞘瘤采用显微手术（MS）、立体定向放射治疗（SR）、保守治疗（CM）和化疗（ChT）的有效听力保留和肿瘤控制结果。
通过 Ovid MEDLINE 对从 1948 年至 2013 年 2 月的英文文献进行了全面检索。
患者必须在诊断时具有有用的听力，并作为主要治疗方法之一接受 4 种治疗中的一种。所有散发性前庭神经鞘瘤病例均被排除。
共回顾了 19 篇文章。听力保留定义为有用听力不变或改善。肿瘤控制定义为 SR、CM 和 ChT 治疗病例大小无变化或肿瘤消退，MS 治疗病例无复发。
MS 的总体结果似乎最差，而 SR 具有很好的肿瘤控制效果，但有用听力保留效果较差。如果患者符合 CM 的条件，他可能会表现出最满意的结果，而可用的治疗方法最少。需要对 ChT 临床试验和可能的副作用进行密切随访，因为初步的短期结果相当有利。需要进一步的长期研究来更好地了解这种疾病。
